Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases

Mi-La Kim, Seok Ju Seong
Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea

The levonorgestrel-releasing intrauterine system (LNG-IUS), originally designed for contraception, has since been applied to various gynecologic diseases. This article summarizes the current status of clinical applications of LNG-IUS to the treatment of gynecologic diseases such as heavy menstrual bleeding, endometriosis, leiomyoma, adenomyosis, endometrial hyperplasia, and early-stage endometrial cancer.

Keywords: Adenomyosis; Endometrial cancer; Endometrial hyperplasia; Endometriosis; Leiomyoma; Levonorgestrel-releasing intrauterine system; Menorrhagia

Introduction

The levonorgestrel-releasing intrauterine system (LNG-IUS), designed initially in the mid-1970s, provides highly effective, safe, and long-term reversible contraception. More than 120 countries, including Korea, have approved it for use [1]. The approved Korean applications include contraception, treatment of heavy menstrual bleeding, treatment of dysmenorrhea, and endometrial protection during estrogen replacement therapy in postmenopausal women. LNG-IUS is a T-shaped device that releases 20 µg/day of LNG into the uterine cavity over a 5-year period [2]. LNG-IUS provides, by contrast with the relatively low serum levels, locally high concentrations of LNG in the endometrium and adjacent tissues. This leads to decidualization of the stroma, mucosal thinning, and eventually, by suppression of endometrial growth, an inactive endometrium [3]. It has been demonstrated that LNG-IUS, additionally to its high contraceptive efficacy, benefits women also in the treatment of gynecologic diseases related to heavy menstrual bleeding and dysmenorrheal, which include endometriosis, leiomyoma, adenomyosis, endometrial hyperplasia, and early-stage endometrial cancer [4,5]. In this article, we summarize the current clinical applications status of LNG-IUS as relates to gynecologic diseases.

Heavy Menstrual Bleeding

Heavy menstrual bleeding (HMB), clinically defined as greater than 80 mL of blood loss per menstrual cycle, is a common health problem in women. Hysterectomy is an often-employed treatment option, though various alternative approaches, such as tranexamic acid, nonsteroidal anti-inflammatory drugs, danazol, combined oral pills, progestins, and LNG-IUS, also can be successful.

Hurskainen et al. [6] conducted a 5-year randomized comparison of clinical outcomes and costs associated with the use of LNG-IUS and hysterectomy for treatment of HMB. In the results, patient satisfaction and quality of life were similar, but costs were 40% lower in the LNG-IUS group. Lethaby et al. [7] published a review of ten randomized controlled trials with reproductive-aged women treated with LNG-IUS versus medical (cyclic progestins) or surgical therapy (hysteroscopic endometrial resection, thermal ablation, or hysterectomy). LNG-IUS
was more effective than cyclic progestins; and whereas side
effects were more common, the LNG-IUS patients were more
satisfied with their results. Endometrial ablation was more
effective than LNG-IUS for reduction of menstrual blood loss,
yet there was no difference in patient’ satisfaction be-
tween the groups. Once again, women treated with LNG-IUS
experienced more drug-induced side effects, but there was
no significant difference in their perceived quality of life. Compar-
ing LNG-IUS with hysterectomy, the former was more cost ef-
factive, and there were no significant differences in the quality
of life measures [7]. Gupta et al. [8] conducted a multicenter,
randomized controlled trial involving 571 women with HMB
who were treated with LNG-IUS or the usual medical therapy
(tranexamic acid, mefenamic acid, combined estrogen-pro-
gestogen, or progestogen alone). In both groups, the patient-
reported scores on the menorrhagia multi-attributes scale
(MMAS) improved from the baseline to six months, though
the LNG-IUS group showed significantly better improvement
sustainment over a 2-year period (P<0.001). Moreover, all of
the MMAS domains showed significantly superior improve-
ments for the LNG-IUS group. Also, at 2 years, the LNG-IUS
group had a higher continuation rate than the usual-medical-
treatment group (64% vs. 38%, P<0.001), with no significant
differences in the rates of hysterectomy, endometrial ablation
or sexual activity scores [8]. The LNG-IUS is a good alternative
to surgical management such as hysterectomy and endome-
trial ablation in heavy menstrual bleeding. In ESHRE Capri
Workshop Group [9], they recommended that the LNG-IUS or
other medical treatments firstly adopted in treatment of HMB.
Overall, LNG-IUS was proved to be highly effective in reducing
menstrual blood loss, was well tolerated, boasted a high user-
satisfaction rate, and was cost effective [9]. Currently, LNG-
IUS is considered to be the first-line treatment for HMB [10].

Endometriosis

Endometriosis is associated with dysmenorrhea, dyspareunia,
non-cyclic pelvic pain, and subfertility. For women with dys-
menorrhea, reported endometriosis incidences have been as
high as 40% to 60% [11,12]. Endometriosis is a chronic dis-
ease that has a recurrence rate of approximately 10% to 15%
one year after conservative surgical treatment alone, and fully
40% to 50% at 5 years’ follow-up [13,14]. Cheong et al. [15],
having conducted a retrospective study, reported re-operation
rate as high as 51% for a 10-year period. Recurrence is an
important issue indeed, as repeated surgery can significantly
impact upon the patient’s quality of life and endanger her
future fertility [16]. In order to prolong symptom-free interval
and prevent recurrence, postoperative adjunctive hormonal
therapy usually is prescribed. Gonadotropin releasing hor-
-mone (GnRH) agonist, danazol, combined oral contraceptives,
and progestins are the common hormonal methods employed
for the management of endometriosis-related pain. GnRH
agonist is the gold standard for adjunctive treatment of end-
ometriosis [17]. Such treatment often needs to be continued
many years or until pregnancy is desired. Although effective,
the hypoestrogenism induced by the GnRH agonist is associ-
ated with systemic side effects, which can affect patient’ com-
pliance and preclude long-term use. Thus, new therapeutic
options, including the continuous use of oral pills or LNG-IUS,
are being explored [18-21].

Several hypotheses have been formulated to explain the
mechanism of action of LNG-IUS in endometriosis-related pain.
One is a local effect on the ectopic endometrium resulting from
depletion of the estrogen and progesterone receptors though
inhibition of synthesis and expression of estrogen and progestin
receptors [22,23]. Other possibilities are a direct effect on the
eutopic endometrium by inhibition of endometrial production
of estrogen-induced growth factors or growth factor-binding
protein, as resulting in an anti-proliferative effect, glandular
atrophy and decidualization [24]. Or, the LNG-IUS effect might
be a function of a reduction of local vascular angiogenesis, a
reduction in pelvic-vessel congestion and an increase in apop-
tosis, a reduction in peritoneal fluid macrophage activity and
a modification in the production of cytokines responsible for
maintenance of lesions and pain [25-28].

LNG-IUS was first used for endometriosis-related dysmen-
orrhea by Vercellini et al. [29]. They reported that it greatly
reduced menstrual pain and was highly rated in terms of pa-
tient satisfaction. As a follow-up to this pilot study, Vercellini
et al. [30] thoroughly investigated the application of LNG-IUS
to endometriosis in a randomized controlled trial, comparing
it with expectant management after laparoscopic conserva-
tive surgery. According to a post-12-month evaluation, and an
intention-to-treat analysis, postoperative recurrence of dys-
menorrhea was significantly decreased in the LNG-IUS group
(10% vs. 45%, P=0.03). Tanmahasamut et al. [31], similarly,
conducted a double-blind randomized controlled trial with 55
post-conservative-surgery patients. At 12 months, the LNG-
IUS group relative to an expectant group, showed a greater reduction in dysmenorrhea visual analogue scale (VAS) (-81 mm vs. -50 mm, \( P=0.06 \)) and pelvic pain VAS (-48.5 mm vs. -22 mm, \( P=0.038 \)). Recurrent dysmenorrhea within one year also was reduced in the LNG-IUS group (7.4% vs. 39.1%, \( P=0.014 \)) [31]. Petta et al. [32] conducted a multicenter randomized controlled trial to compare LNG-IUS (n=39) with a GnRH agonist (n=43), finding no statistical differences in VAS pain score or quality-of-life improvement. However, Bayoglu et al. [33] reported different results for a 12-month prospective randomized study involving 40 severe endometriosis patients. They reported that the total endometriosis severity profile (TESP) score decreased in the LNG-IUS group over the initial 6 months, but that by 12 months of follow-up, the TESP scores had risen back to values similar to those at pretreatment. At the end of the study, the LNG-IUS group relative to the GnRH subjects showed a significant increase in VAS and TESP scores, and recorded lower levels of satisfaction [33]. Even so, given the additional advantages of LNG-IUS, namely the facts that it is not associated with hypoestrogenism and the possibility of long-term (5-year) use, it may yet be used for chronic pelvic pain-associated endometriosis in women who do not wish to conceive.

### Leiomyoma

Leiomyoma is the most common benign gynecologic tumor in reproductive-aged women, producing symptoms including HMB, dysmenorrhea, pelvic pressure and pain, and reproductive dysfunction, though many patients remain asymptomatic [34,35].

In many studies, LNG-IUS use by leiomyoma patients ameliorated leiomyoma-related menorrhagia. This treatment modality is utilized primarily in cases of leiomyoma-related HMB, though treatment is not as effective as for idiopathic HMB [36-41]. Sivin and Stern [42] reported a multicenter prospective 7-year randomized study, the chief finding of which was that long-term use of LNG-IUS reduced the incidence of newly developed myoma and myoma-related surgery in comparison with copper T. However, there is no coherence to changes of uterine volume or leiomyoma volume in users of LNG-IUS [36,41,43].

There are some limitations on the suitability of LNG-IUS for women with leiomyoma, including leiomyomas causing distortion of the uterine cavity or cases of submucosal myoma [44]. The reported LNG-IUS expulsion rates among women with uterine leiomyomas range between 0% and 20%, and are higher than those without uterine leiomyoma (0% to 3%). Also, significantly higher rates of expulsion have been noted among women with greater uterine volumes (a possible proxy for fibroid size) than among those with smaller ones [36-39,45,46].

### Adenomyosis

Adenomyosis characterized by the presence of heterotopic endometrial glands and stroma in the myometrium, is a common cause of menorrhagia and dysmenorrhea. The definitive treatment is hysterectomy, at least traditionally. However, alternative management, including oral pills, danazol, GnRH agonist, LNG-IUS, endometrial ablation/resection, uterine artery embolization, and magnetic resonance guided focused ultrasound also can be considered [47-55].

The use of LNG-IUS for adenomyosis was first reported by Fedele et al. [50], in 1997. They evaluated the efficacy of LNG-IUS in 25 patients suffering from adenomyosis-associated menorrhagia, and found that 92% of them showed decreases on the pictorial blood loss assessment chart (PBAC) and diminished dysmenorrheal symptoms, along with significant increases in hemoglobin, hematocrit, and serum ferritin levels [50]. Bragheto et al. [56] reported on the employment of LNG-IUS in the treatment of 29 adenomyosis patients diagnosed and monitored by magnetic resonance imaging. After 6 months, significant reductions of junctional zone thickness and VAS pain scores were observed, though there was no significant change in uterine volume. Cho et al. [57] and Sheng et al. [58] reported 3-year follow-up data on the application of LNG-IUS for the treatment of adenomyosis, in which indicated significantly decreased menorrhagia and VAS pain scores and high patient’ satisfaction. Additionally to these observational study, Ozdegirmenci et al. [59] compared LNG-IUS with hysterectomy in a prospective randomized trial, the results of which showed that the LNG-IUS group enjoyed significant and comparable improvements in hemoglobin levels and along with superior health-related quality of life improvements during the first year. Conclusively, LNG-IUS is an effective treatment option for management of dysmenorrhea and menorrhagia in patients with clinically diagnosed...
adenomyosis. As such, it offers patients a practical alternative to hysterectomy.

**Endometrial Hyperplasia**

Endometrial hyperplasia is defined as a morphologic and biologic alteration of the endometrium as a result of continuous estrogenic stimulation unopposed by adequate levels of progesterone. Among reproductive-aged women, chronic anovulation, commonly seen in those diagnosed with polycystic ovarian syndrome, is the most common cause of endogenous unopposed estrogen [60].

Hormonal therapy is regarded as the standard management plan for endometrial hyperplasia without atypia or benign endometrial hyperplasia, owing to the facts that the malignancy potential is low, the spontaneous resolution rate is high, and the response to hormonal therapy, moreover, is also high [61,62]. In the case of atypical endometrial hyperplasia, total hysterectomy with or without bilateral salpingooophorectomy is the current standard treatment option [63]. However, hormonal therapy can be selected in atypical endometrial hyperplasia patients who desire to preserve their fertility or in patients who are poor surgical candidates due to severe medical comorbidities. The hormonal classes with potential therapeutic options include progestins, selective estrogen receptor modulators, aromatase inhibitors, and gonadotropin-releasing hormone agonists. Among these, progestin is most commonly used as the safe, uterus-preserving alternative to hysterectomy. Nonetheless, systemic side effects and poor compliance reportedly are associated with oral progestin; clinical trials of progestin therapies for atypical endometrial hyperplasia, furthermore, have not yet established a standard regimen [64-66].

Compared with oral progestin, LNG-IUS in many studies has been found to have less severe systemic side effects and higher efficacy as a treatment for endometrial hyperplasia [66-71]. Gallos et al. [72] recently published a systematic review and meta-analysis of 24 studies that had compared endometrial hyperplasia regression rates between oral progestin and LNG-IUS for a total of 1,001 patients. In cases of simple hyperplasia, 213 women (9 studies) treated with oral progestin showed a pooled regression rate of 89%, versus the 96% rate for 72 LNG-IUS patients (6 studies). Meta-regression confirmed that these rates were not statistically significant ($P=0.41$). In cases of complex hyperplasia, 389 patients (9 studies) administered oral progestin showed a pooled regression rate of 66%, versus the 92% rate for 102 LNG-IUS patients (4 studies). Overall, the treatment outcomes for LNG-IUS were statistically more significant than those for oral progestin ($P<0.01$). In atypical hyperplasia, 189 women (14 studies) treated with oral progestin showed a pooled regression rate of 69%, versus the 90% rate for 36 LNG-IUS patients (7 studies) ($P=0.03$) [72].

Lee et al. [73] reported on the effectiveness of LNG-IUS in 12 patients (4 simple, 7 complex, 1 atypical complex hyperplasia) evaluated at our institution in Korea. In all of the cases, complete regression of endometrial hyperplasia was achieved. The mean duration to regression was 4.5 months (66% achieved complete regression within 3 months), and all of the patients had achieved regression within 9 months. Additionally, a prospective multicenter trial on Korean women (planned number of patients: 80), this one by the Korean Gynecologic Oncology Group (KGOG2006), has been ongoing since 2006 [74].

**Early-stage Endometrial Cancer**

Endometrial carcinoma is the most common gynecologic malignancy in developed countries [75,76]. The majority of cases are diagnosed in postmenopausal women, and up to 14% of patients are premenopausal, among whom 3% to 5% are aged under 40 years, 70% of those 3% to 5% being nulliparous at the time of diagnosis [77,78]. On histologic examination, 84% of all endometrial cancers are endometroid adenocarcinomas, which typically have a good prognosis [79]. Endometrial cancer in younger women usually is most commonly of the early clinical stage, well-differentiated and endometrioid type, which also carries a good prognosis [80]. The current standard treatment is total hysterectomy and bilateral salpingooophorectomy with or without surgical staging [81-83]. However, the data from multiple studies suggest that for select patients with early clinical stage carcinoma and a strong desire to maintain fertility, hormonal therapy is an attractive and effective alternative [84-88].

Progestins are the first medical treatment option for endometrial cancer. Progestins effect secretory differentiation of endometrial glands, inhibit estrogen receptor function and endometrial cell mitosis, and promote apoptosis; additionally,
some progestins have an anti-angiogenic effect [89]. According to a meta-analysis by Gallos et al. [90], a total 408 women (32 studies) who underwent fertility-sparing treatment by various methods, including progestin, LNG-IUS, GnRH agonist, aromatase inhibitor, and hysteroscopic resection, showed a pooled regression rate of 76.2%, a relapse rate of 40.6%, and a live birth rate of 28%.

Montz et al. [91] reported the results of LNG-IUS-based treatment of the International Federation of Gynecology and Obstetrics (FIGO) stage IA, grade 1 endometrioid cancer patients at high risk for perioperative complications. Among 12 patients, the biopsy results were negative for 64% at 6 months and 75% at 12 months. Cade et al. [92] reported on 16 patients who had been treated with MPA (4 patients), LNG-IUS (3 patients), or both (9 patients). Ten of the patients responded to treatment (MPA only, 2; LNG-IUS only, 1; both, 7), and the mean time to response was 5.5 months. The results of 5 young patients who had been treated, at our institution, with a daily 500 mg dose of MPA plus LNG-IUS insertion were published in 2010. Complete remission was achieved for 4 patients, and another one showed partial remission. During the mean 10.2 months follow-up period, there was no recurrence of disease [93]. Also in Korea, a prospective multicenter study (KGOG2009), initiated in 2009, has been treating patients with 500 mg of MPA plus LNG-IUS for early-stage endometrial cancer in young women [94].

Hormonal management with LNG-IUS and supplemental oral progestin appears to be a safe and moderately effective option for early-stage endometrial cancer patients who want to retain their reproductive potential. However, given that the relapse rate is higher than 40% [90], post-childbirth women should consider hysterectomy, which remains the standard of care.

**Conclusion**

The non-contraceptive benefits of LNG-IUS, particularly the effects on heavy menstrual bleeding and dysmenorrhea, as well as the option for 5-year use, add to its utility and efficacy as an alternative to long-term contraception. LNG-IUS in fact has proved to be an effective treatment modality for a great variety of gynecologic conditions: idiopathic, myoma- or adenomyosis-related HMB, endometriosis- or adenomyosis-related pelvic pain, as well as endometrial hyperplasia and early-stage endometrial cancer. However, further large-scale randomized study and comparison with conventional treatment methods, along with long-term follow-up data, are needed.

**References**

1. Salem RM. New attention to the IUD: expanding women’s contraceptive options to meet their needs. Popul Rep B 2006;1-26.
2. Mirena [Internet]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; c2013 [cited 2013 Feb 15]. Available from: http://berlex.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf.
3. Perino A, Quarataro P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 1987;18:137-40.
4. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception 2007;75:S161-6.
5. Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand 2012;91:3-9.
6. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-63.
7. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;(4):CD002126.
8. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368:128-37.
9. ESHRE Capri Workshop Group. Intrauterine devices and intrauterine systems. Hum Reprod Update 2008;14:197-208.
10. Espey E. Levonorgestrel intrauterine system: first-line therapy for heavy menstrual bleeding. N Engl J Med 2013;368:184-5.
11. Prevalence and anatomical distribution of endometriosis in women with selected gynaecological conditions: results from a multicentric Italian study. Gruppo
italiano per lo studio dell’endometriosi. Hum Reprod 1994;9:1158-62.

12. Ajossa S, Mais V, Guerriero S, Paoletti AM, Caffiero A, Murgia C, et al. The prevalence of endometriosis in premenopausal women undergoing gynecological surgery. Clin Exp Obstet Gynecol 1994;21:195-7.

13. Evers JL, Dunselman GA, Land JA, Bouckaert PX. Is there a solution for recurrent endometriosis? Br J Clin Pract Suppl 1991;72:45-50.

14. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update 2009;15:441-61.

15. Cheong Y, Tay P, Luk F, Gan HC, Li TC, Cooke I. Laparoscopic surgery for endometriosis: how often do we need to re-operate? J Obstet Gynaecol 2008;28:82-5.

16. Park HJ, Koo YA, Yoon BK, Choi D. Postoperative long-term maintenance therapy with oral contraceptives after gonadotropin-releasing hormone analog treatment in women with ovarian endometrioma. J Minim Invasive Gynecol 2009;16:34-9.

17. Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2000;(2):CD000346.

18. Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004;(3):CD003678.

19. Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2006;(4):CD005072.

20. Parazzini F, Fedele L, Busacca M, Falsetti L, Pellegrini S, Venturini PL, et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 1994;171:1205-7.

21. Busacca M, Somigliana E, Bianchi S, De Marinis S, Calia C, Candiani M, et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum Reprod 2001;16:2399-402.

22. Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril 1978;29:397-401.

23. Hurskainen R, Salmi A, Paavonen J, Teperi J, Rutanen E. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel. Mol Hum Reprod 2000;6:1013-8.

24. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65:699-702.

25. Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 2001;16:2103-8.

26. Ramey JW, Archer DF. Peritoneal fluid: its relevance to the development of endometriosis. Fertil Steril 1993;60:1-14.

27. Kupker W, Schultz-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update 1998;4:719-23.

28. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996;98:482-9.

29. Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999;72:505-8.

30. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003;80:305-9.

31. Tanmahasamut P, Rattanachaiyanont M, Aungswathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postsurgical medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 2011;95:492-6.
34. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996;41:483-90.
35. Stewart EA. Uterine fibroids. Lancet 2001;357:293-8.
36. Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007;75:193-8.
37. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005;59:29-35.
38. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003;79:1194-8.
39. Mercorio F, De Simone R, Di Spiezio Sardo A, Cerrota G, Bifulco G, Vanacore F, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003;67:277-80.
40. Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. J Minim Invasive Gynecol 2008;15:735-8.
41. Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril 2010;94:371-4.
42. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-7.
43. Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet 2012;116:35-8.
44. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-13.
45. Ikomi A, Mansell E, Spence-Jones C, Singer A. Treatment of menorrhagia with the levonorgestrel intrauterine system: can we learn from our failures? J Obstet Gynaecol 2000;20:630-1.
46. Rosa e Silva JC, de Sa Rosa e Silva AC, Candido dos Reis FJ, Manetta LA, Ferriani RA, Nogueira AA. Use of a levonorgestrel-releasing intrauterine device for the symptomatic treatment of uterine myomas. J Reprod Med 2005;50:613-7.
47. Rabinovici J, Stewart EA. New interventional techniques for adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:617-36.
48. Takebayashi T, Fujiwara Y, Umesaki N, Ogita S. Danazol suspension injected into the uterine cervix of patients with adenomyosis and myoma: preliminary study. Gynecol Obstet Invest 1995;39:207-11.
49. Nelson JR, Corson SL. Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report. Fertil Steril 1993;59:441-3.
50. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-9.
51. Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update 1998;4:323-36.
52. Benagiano G, Brosens I, Carrara S. Adenomyosis: new knowledge is generating new treatment strategies. Womens Health (Lond Engl) 2009;5:297-311.
53. Phillips DR. Endometrial ablation for postmenopausal uterine bleeding induced by hormone replacement therapy. J Am Assoc Gynecol Laparosc 1995;2:389-93.
54. Englander MJ. Uterine artery embolization for the treatment of adenomyosis. Semin Intervent Radiol 2008;25:387-93.
55. Yoon SW, Kim KA, Cha SH, Kim YM, Lee C, Na YJ, et al. Successful use of magnetic resonance-guided focused ultrasound surgery to relieve symptoms in a patient with symptomatic focal adenomyosis. Fertil Steril 2008;90:2018.e13-5.
56. Braghetto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007;76:195-9.
57. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008;198:373.e1-7.

58. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009;79:189-93.

59. Ozdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95:497-502.

60. Whiteman MK, Zapata LB, Tepper NK, Marchbanks PA, Curtis KM. Use of contraceptive methods among women with endometrial hyperplasia: a systematic review. Contraception 2010;82:56-63.

61. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403-12.

62. Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y. Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet 2001;265:85-8.

63. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-9.

64. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006;125:259-64.

65. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol 2012;120:1160-75.

66. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 2001;15:393-405.

67. Wildemeersch D, Janssens D, Pylvser K, De Wever N, Verbeek G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210-3.

68. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73.

69. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-75.

70. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 2006;101:214-23.

71. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003;91:526-33.

72. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1-10.

73. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol 2010;21:102-5.

74. Lee TS, Seong SJ, Kim JW, Ryu HS, Song ES, Nam BH. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006). Jpn J Clin Oncol 2011;41:817-9.

75. Surveillance epidemiology and end results. SEER Stat fact sheets: corpus and uterus, NOS [Internet]. Bethesda, MD: US National Cancer Institute; [cited 2013 Feb 15]. Available from: http://seer.cancer.gov/statfacts/html/corp.html.

76. Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 2002;14:67-73.
77. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20.

78. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105:575-80.

79. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S105-43.

80. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 2004;117:132-7.

81. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9.

82. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41.

83. Leitao MM, Barakat RR. Advances in the management of endometrial carcinoma. Gynecol Oncol 2011;120:489-92.

84. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.

85. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8.

86. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997;79:320-7.

87. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001;167:39-48.

88. Gottlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718-25.

89. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 1998;83:111-21.

90. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012;207:266.e1-12.

91. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-7.

92. Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG 2010;117:879-84.

93. Kim MK, Yoon BS, Park H, Seong SJ, Chung HH, Kim JW, et al. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer 2011;21:673-7.

94. Kim MK, Seong SJ, Lee TS, Kim JW, Nam BH, Hong SR, et al. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KOGOG2009). Jpn J Clin Oncol 2012;42:1215-8.